Douglas Treco

Douglas Treco, Ph.D., is CEO and board chairman at Inozyme Pharma Inc. (INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of severe conditions affecting the vasculature, soft tissue, and skeleton. Among his previous accomplishments, Dr. Treco co-founded Transkaryotic Therapies, Inc., which produced a number of rare disease drugs. He was also co-founder, president, and CEO of Ra Pharmaceuticals, which was acquired in April 2020 by UCB S.A. for $2.5 billion. Zilucoplan, Ra’s lead program for the treatment of myasthenia gravis, is currently under review for marketing approval in the United States and European Union. A molecular biologist by training, Dr. Treco has long dedicated himself to pioneering solutions in rare disease therapeutics. He was previously a visiting scientist in the Department of Molecular Biology at Massachusetts General Hospital and a lecturer in genetics at Harvard Medical School from 2004 to 2007. He holds a B.A. in Biology from the University of Delaware, a Ph.D. in Biochemistry and Molecular Biology from the State University of New York at Stony Brook, and performed post-doctoral research at the Salk Institute for Biological Studies and Massachusetts General Hospital.